NPAT up 52.1% on Automation divestment; continuing operations grew just 6.2%

Continuing-operations NPAT of $35.6m was up 6.2% from $33.5m on the restated basis, and continuing PBT was $49.6m at a 28.3% effective rate.

On a continuing-operations basis the release describes revenue of $169.4m as up 5.4% from a restated $160.7m and EBITDA of $61.2m as up 4.7% from $58.4m. Comparing the same $169.4m to the previously reported HY21 total of $169.7m (which still included Automation) gives the canonical -0.2% line.

Operating cash flow doubled to $21.9m from $10.8m, capex eased to $8.2m from $15.5m, and pre-lease FCF turned to $13.7m from -$4.7m. Cash stood at $48.6m.

The Automation divestment dominates the headline. The $15.2m discontinued-operations gain accounts for the entire gap between +52.1% reported NPAT and +6.2% continuing NPAT, so the cooperative's underlying earnings trajectory is the +6.2% line, not the headline.

2. Cash generation strengthened independently of the divestment. OCF rose 102.6%, cash conversion moved to 35.8% from 18.0%, and capex intensity fell to 4.8% of revenue from 9.1%. Pre-lease FCF turning positive partly reflects a HY21 base that management had previously attributed to tax-payment and receipts timing.

3. NZ market genetics anchors the continuing portfolio at 57.6% of revenue ($97.5m revenue, $66.1m segment result). Farm software ($26.3m, 15.5%) and diagnostics ($11.7m, 6.9%) are the smaller engines management is now leaning on after exiting Automation. Prior-period segment splits on a restated basis are not supplied, so trend across segments cannot be read here.

The full-year shape is distorted by the Automation reclassification, but the supplied HY21 vs FY21 pattern still matters: HY21 NPAT of $33.4m exceeded FY21 NPAT of $22.9m, meaning H2 last year was loss-making at the bottom line. That heavy first-half weighting is consistent with LIC's spring-loaded artificial breeding revenue and should temper any straight-line extrapolation of HY22 continuing earnings into FY22. The release does not quantify the second-half outlook on the new continuing-operations basis.

EBITDA growth of 4.7% on the restated continuing basis broadly tracks continuing revenue growth of 5.4%, and the 28.3% effective tax rate is unremarkable. Equity grew to $327.3m from $294.1m, with a meaningful portion of that uplift attributable to the divestment gain rather than retained operating profit.

Cash conversion improvement is partly real and partly timing. Capex falling 47.4% is a genuine intensity drop, but receivables of $85.9m equate to 92.3 receivable days, reflecting LIC's seasonal billing cycle to dairy farmers around spring mating. Half-year operating cash is therefore inherently working-capital sensitive, and the FCF-to-NPAT ratio of 27.0% confirms that cash earnings still lag accounting earnings at the half. The Automation sale proceeds also sit inside the $48.6m cash balance, which flatters balance-sheet optics relative to operating cash generation alone.

This briefing cannot assess the standalone economics of the divested Automation business or whether the sale multiple is favourable relative to its run-rate contribution.